This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.
Smolen, J., Emery, P., Ferraccioli, G., Samborski, W., Berenbaum, F., Davies, O., Koetse, W., Purcaru, O., Bennett, B., Burkhardt, H., Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial, <<ANNALS OF THE RHEUMATIC DISEASES>>, 2015; 74 (5): 843-850. [doi:10.1136/annrheumdis-2013-204632] [http://hdl.handle.net/10807/71518]
Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial
Ferraccioli, Gianfranco;
2015
Abstract
This 52-week, randomised, double-blind phase IIIb study assessed efficacy and safety of certolizumab pegol (CZP) as add-on therapy to non-biologic disease-modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients with low to moderate disease activity, and stopping therapy in patients in sustained remission.
| File | Dimensione | Formato | |
|---|---|---|---|
|
843.full.pdf
accesso aperto
Tipologia file ?:
Versione Editoriale (PDF)
Licenza:
Creative commons
Dimensione
2.51 MB
Formato
Adobe PDF
|
2.51 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
